Candidate arguments for counsel, ranked strongest-first — brainstorming inputs for counsel to evaluate, not a drafted response.
1In re Spada inherency misapplied — NAC and NACA are structurally distinct, so NAC's PK is not necessarily NACA's
Mischaracterized referenceClaim 10Claim 11Claim 12Claim 13Claim 14Claim 25Rebuts: §103 rejection of claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
mean plasma concentrations of NACA ... after administration ... to a human
The examiner relies on In re Spada for the proposition that identical chemical structure means the disclosed properties are necessarily present. But Arad's retrieved text discloses plasma concentrations of NAC, and NACA (N-acetylcysteine amide) is a structurally distinct compound from NAC — the Spada 'identical chemical structure' predicate is not met, so a NAC plasma value does not necessarily establish the claimed NACA plasma value. The examiner's own qualifier — that the compositions reach effective plasma concentrations 'for NAC and presumably NACA' — signals that the NACA PK is inferred rather than disclosed. For counsel to weigh: inherency requires that the property be necessarily present, not merely probable or possible (MPEP § 2112).
- —Office action Rejection 2: 'if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada...'
- —Office action Rejection 2: '...reaches a therapeutically effective plasma concentration over time (para. 2) for NAC and presumably NACA depending on the active agent of choice'
- —Arad claim 1 (plasma concentration expressed for N-acetylcysteine, generically)
MPEP § 2112 / § 2112.01 — inherency requires necessity, not probability; § 2145 — attacking the inherency premise of the combination
Risk The examiner may respond that NACA is Arad's 'amide' active, so the same PK teaching applies, and that claim 10 recites both NACA and NAC concentrations. Prosecution-history caution: emphasizing that NACA is a structurally distinct compound with distinct properties from NAC could narrow how 'NACA' and any prodrug relationship are later construed.
Likely examiner response✓ survives — strong
A realistic examiner rebuttal: on a § 103 footing the examiner can argue the claimed NACA plasma-concentration values are simply the inherent/natural result of administering the (asserted-obvious) NACA composition at the claimed dose, shifting the burden to applicant to show the PK actually differs (product/property burden-shifting, MPEP § 2112.01). The examiner may also argue NACA, as the amide of NAC, would be expected to exhibit predictable/comparable pharmacokinetics, so the reliance on structural relationship is not pure Spada mechanics.
How to adjust This rests on an incontrovertible record fact — NAC and NACA are distinct compounds — so the Spada 'identical chemical structure' predicate is not met, and the examiner's own 'presumably NACA' qualifier signals inference rather than necessity (MPEP § 2112 requires the property be NECESSARILY present, not probable). Shore it up by squarely rebutting any burden-shift: the shift only arises once the underlying composition is shown obvious, which arguments 1–2 contest. Keep this near the top and couple it with argument 5. If applicant possesses NACA-specific PK data diverging from NAC, a § 1.132 declaration would convert this from argument to evidence.
A tablet comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient
On the fully-grounded text (abstract; claim 1), Arad is directed to a controlled-release composition of NAC that provides 'a therapeutically effective plasma concentration of N-acetylcysteine over more than about 2 hours,' built around release-rate controlling polymers, matrix systems, osmotic push/pull layers with release-rate controlling membranes, and coated particles (Arad claims 10-34). The examiner extracts individual excipients from these controlled-release architectures and reassembles them into a simple NACA tablet 'with a reasonable expectation of success,' but Arad's retrieved teachings concern NAC (a different active than the claimed NACA) and excipients whose recited function is release-rate control. For counsel to weigh: a PHOSITA as construed in OA4 would not, on Arad's actual teachings, have had a reasonable expectation that lifting excipients out of Arad's release-controlling systems and combining them with NACA would yield the claimed tablet compositions. OA4 grades this weakness 'strong.'
- —Arad abstract: 'a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time'
- —Arad claim 1: 'provides a therapeutically effective plasma concentration of N-acetylcysteine over more than about 2 hours'
- —Arad claims 10-34 (matrix, osmotic push/pull layers, release-rate controlling membranes, coated particles)
- —Office action Rejection 1: '...to select the different combinations of ingredients to arrive at the claimed invention with a reasonable expectation of success.'
MPEP § 2143.02 — obviousness requires a reasonable expectation of success grounded in the references' actual teachings, not a hope; see also § 2143.01 (rational underpinning)Evidence needed: A § 1.132 declaration addressing unpredictability of translating NAC controlled-release excipient selections to a NACA tablet, and/or the distinct formulation behavior of NACA vs NAC, would strengthen this point.
Risk The examiner will respond that a 'tablet' is a conventional dosage form and that Arad discloses tablets (para. 67) and generic excipients, so success was predictable. Prosecution-history caution: characterizing the claimed tablet as necessarily immediate-release or as distinct from Arad's controlled-release systems may narrow claim scope in the file wrapper — claim 1 as written does not recite a release profile, so counsel should weigh whether to argue this without an amendment.
Likely examiner response◐ survives — moderate
A realistic examiner rebuttal: under the KSR combining-known-elements rationale (MPEP § 2143(A)) reasonable expectation of success does not require certainty (MPEP § 2143.02), and the excipients at issue are conventional pharmaceutical formulation components whose behavior in a tablet is predictable; the examiner can note that Arad's available abstract itself describes both sustained-release (SR) AND immediate-release (IR) components, so Arad is not confined to release-rate-controlled architectures, and that selecting known excipients for a simple tablet 'yield[s] no more than one would expect.' The examiner can also press that attacking Arad's controlled-release framing attacks the reference individually rather than the combination as applied (MPEP § 2145).
How to adjust The strongest grounded hook is that Arad's retrieved claims recite the excipients specifically for release-rate-control function and that the active is NAC, not NACA — pair this REOS point with argument 4's structural-distinctness fact rather than running it alone. Confirm exactly what the retrieved abstract says about IR components before conceding Arad is 'controlled-release only.' If the excipient-function distinction cannot be tied to fully-retrieved text (most excipient paragraphs were not retrieved per OA2), consider an amendment concept that recites tablet-specific/immediate-release structural or performance features that distinguish Arad's release-controlling systems, rather than resting on REOS argument alone.
N-acetylcysteine amide (NACA)
Arad's retrieved claims recite NAC 'or a salt, solvate, prodrug, and/or analog thereof,' and only generically 'an amide prodrug' (claim 6), alongside a long list of specifically named analogs (claim 8) — none of which is NACA. The examiner's equation of 'amide' with NACA rests on Arad para. 26, a specification paragraph that was not retrieved (OA2), so that reading cannot be confirmed against the record. Even taking the generic 'amide prodrug' language as given, whether a PHOSITA would arrive at the specific compound NACA from Arad's broad genus of prodrugs and analogs is a genus-to-species question the KSR combination-of-known-elements boilerplate does not address. For counsel: verify Arad para. 26 to confirm what it actually names before relying on this distinction, then weigh the genus/species framing.
- —Arad claim 6: 'a prodrug of N-acetylcysteine selected from the group consisting of an ester prodrug, an amide prodrug, and an anhydride prodrug'
- —Arad claim 8 (long list of named analogs, none identified as NACA)
- —Office action Rejection 1: 'Arad teaches tablet (para. 67) compositions comprising NAC that may comprise amide (para. 26), which is interpreted as NACA.'
- —OA2: '¶26 ... in the specification, which is NOT part of the available text ... cannot be confirmed or contradicted'
MPEP § 2144.08 / § 2143 — selecting a species from a disclosed genus requires articulated reasoning; a generic mention is not a specific disclosure of the speciesEvidence needed: Retrieve and confirm Arad para. 26 to see whether it names NACA specifically.
Risk The examiner will likely stand on para. 26 as naming the amide (NACA) and reassert KSR. Because para. 26 is unretrieved, the NACA-reading portion is verify-first; the fully-grounded portion (claims 6 and 8) supports only the genus/species framing. Prosecution-history caution: arguing NACA is a distinct, non-obvious species over Arad's amide-prodrug genus may be used later to narrow the reach of 'NACA' in the claims.
Likely examiner response◐ survives — moderate
A realistic examiner rebuttal: NACA is literally N-acetylcysteine amide — i.e., the amide of NAC — so the examiner can maintain that Arad's generic 'amide prodrug' language (claim 6) reads on NACA directly, and that Arad para. 26 (which the examiner cites) names it specifically. Where a genus is limited or the species is an expressly contemplated member, the examiner can invoke genus-to-species obviousness (envisaging a member of a small/finite class) rather than the bare combination boilerplate.
How to adjust This argument is contingent on Arad para. 26, which was NOT retrieved (OA2) — verify para. 26 FIRST. If para. 26 names NACA, this distinction collapses and counsel should not press it. If para. 26 does not name NACA and the genus is broad, reframe as a genus-to-species selection lacking any articulated reason to pick NACA from the listed prodrugs/analogs (claim 8 names specific analogs, none NACA on the retrieved record). Do not present the 'amide ≠ NACA' point as strong until para. 26 is confirmed.
Conclusory KSR rationale for the specific four-component excipient combination of claim 2
Conclusory rationaleClaim 2Claim 3Claim 4Claim 5Claim 6Claim 7Claim 8Claim 9Rebuts: §103 rejection of claims 1, 2, 3, 4, 5, 6, 7, 8, 9
microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acid
The office action expressly admits 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2,' and bridges the gap only with generic KSR combination-of-known-elements boilerplate and the assertion that selecting combinations 'yield[s] no more than one would expect.' Of the four components, only lactose monohydrate is confirmable in Arad's retrieved text, and there it appears solely as an osmagent for osmotic systems (Arad claim 26), not as a tablet filler; the other three are cited to specification paragraphs (82, 84, 85) that were not retrieved (OA2). For counsel to weigh: the rejection supplies no articulated reason, tied to Arad's actual teachings, why a PHOSITA would assemble this particular four-component set or draw lactose monohydrate from an osmotic-layer context into the claimed tablet. Verify Arad paras. 82, 84, 85 to confirm whether the three unconfirmed components are even individually disclosed.
- —Office action Rejection 1: 'Arad does not teach an exact combination of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and stearic acid recited in claim 2.'
- —Arad claim 26 (lactose monohydrate listed among osmagents for the osmotic pull layer)
- —OA2: 'the paragraph-numbered disclosures the examiner relies on (¶... 82, 84, 85 ...) are in the specification, which is NOT part of the available text'
MPEP § 2143.01 — a § 103 rejection must rest on articulated reasoning with a rational underpinning; a bare 'would have been obvious' is legally insufficient; see also § 2143 (KSR rationales require factual findings)Evidence needed: Retrieve Arad paras. 82, 84, 85 to confirm whether microcrystalline cellulose, croscarmellose sodium, and stearic acid are individually disclosed and in what context.
Risk The examiner will likely reassert KSR/Sakraida — that arranging old excipients performing their known functions is obvious — and cite the unretrieved paras as evidence each component is disclosed. If paras. 82/84/85 do disclose the three components as tablet excipients, the combination argument weakens to a pure 'no articulated reason to pick this set' point. No PHE concern beyond narrowing the excipient set if counsel amends to it.
Likely examiner response◐ survives — moderate
A realistic examiner rebuttal: microcrystalline cellulose, croscarmellose sodium, and stearic acid are ubiquitous, well-understood tablet excipients (filler, disintegrant, lubricant), and the examiner can readily supply the missing articulation — that combining conventional excipients for their known purposes yields predictable results (MPEP § 2143(A)) and that selecting among known suitable excipients is routine formulation optimization — curing the 'conclusory' defect the applicant identifies. The examiner cited paras. 82, 84, 85 for these components; if those paragraphs disclose them, the individual-disclosure objection falls away.
How to adjust Verify Arad paras. 82, 84, 85 FIRST (not retrieved per OA2). The lactose-monohydrate-as-osmagent point (Arad claim 26) is grounded and worth pressing — that the only confirmable component appears in an osmotic-layer context, not as a tablet filler. But the broader 'conclusory rationale' attack is easily curable by the examiner supplying standard formulation reasoning, so it is not a durable stand-alone. Where the components are conventional, the more productive posture may be an amendment tied to a demonstrated criticality/unexpected result of the specific four-component set (§ 1.132 evidence), rather than arguing the rationale is conclusory.
corresponding wt.% ranges for lactose, microcrystalline cellulose, croscarmellose sodium, and stearic acid
For the narrow numeric ranges of claims 6-9 and 20-24 (e.g., stearic acid about 0.1-5.6 wt.%, croscarmellose sodium about 0-9 wt.%), the rejection reasons that the 'about 10-90%' active-agent range in Arad leaves a remainder that 'may be excipients, fillers, additives, etc.' The office action offers no articulated route from Arad's teachings to these specific excipient percentages; the only apparent roadmap to the claimed component-by-component ranges is the applicant's own specification. For counsel to weigh: OA4 flags hindsight reconstruction as a 'moderate' weakness, and the § 103 analysis may not draw its motivation solely from the applicant's disclosure.
- —Office action Rejection 1: 'since the amount of active agent may be "about" 10-90% (para. 87), it is interpreted that the remaining amount ("about" 10-90%) may be excipients, fillers, additives, etc.'
- —OA4 combination weakness: 'hindsight_reconstruction (moderate)'
- —Claims 6-9 and 20-24 recite specific wt.% ranges per component
MPEP § 2145 / § 2143.01 — the motivation to arrive at the claimed subject matter may not be gleaned only from the applicant's disclosure (impermissible hindsight)Evidence needed: A § 1.132 declaration showing criticality or unexpected results for the claimed excipient ranges would materially strengthen this point if the examiner invokes routine optimization.
Risk The examiner may respond that optimizing excipient amounts is routine result-effective-variable work (MPEP § 2144.05) within the disclosed remainder, shifting the burden to applicant to show criticality. Prosecution-history caution: arguing criticality of specific ranges may require, and may commit applicant to, evidence of unexpected results tied to those ranges.
Likely examiner response◐ survives — moderate
A realistic examiner rebuttal: where the prior art discloses a general range (Arad's 'about 10-90%' active, leaving a remainder for excipients), the specific claimed weight-percent ranges are prima facie obvious as routine optimization of result-effective variables (MPEP § 2144.05), and overlapping/adjacent ranges support obviousness absent a showing of criticality. The examiner can characterize the 'hindsight' objection as unsupported because the ranges fall within or optimize a range the art already discloses.
How to adjust OA4 already grades hindsight 'moderate'; the routine-optimization/§ 2144.05 comeback is a strong examiner tool, so pure attorney argument that the ranges 'track the applicant's disclosure' is unlikely to carry alone. The recognized rebuttal to routine optimization is evidence of criticality or unexpected results commensurate with the claimed ranges (MPEP § 2145) — i.e., a § 1.132 declaration. Consider amend-plus-evidence for the narrow numeric ranges of claims 6-9/20-24 rather than resting on the hindsight framing.
NACA-specific plasma-concentration profile not shown on the record (verify-first as to chemm)
Missing elementClaim 10Claim 11Claim 13Claim 25Rebuts: §103 rejection of claims 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
mean plasma concentrations of NACA ... ranging from about 200 to 1200 ng/mL after administration ... to a human
On the examiner's own characterization, chemm.hhs.gov reports a NAC peak (350-400 ng/mL for a 200-400 mg NAC oral dose within 1-2 hours), not a NACA plasma concentration, and Arad's retrieved text supplies no NACA-specific PK value. The NACA half of the claimed range therefore appears, on the present record, to be supplied only by the examiner's 'presumably NACA' reasoning and the contested Spada inherency premise. Because chemm is unverifiable and is taken as given, its content cannot be contested — this is a verify-first candidate: counsel should obtain and verify chemm.hhs.gov pg. 11 to confirm whether it supplies any NACA plasma-concentration teaching before treating the NACA half of the range as absent. This candidate is provisional and non-dispositive and ranks below the fully-grounded arguments above.
- —Office action Rejection 2: 'chemm.hhs.gov teaches that after an oral dose of 200-400 mg of NAC, a peak plasma concentration of 0.35-4 mg/L (350-400 ng/mL) is achieved within 1-2 hours (pg. 11).'
- —Claim chart (OA3): 'Arad's available text ... contains no NACA-specific pharmacokinetic value'
- —OA3 posture note: 'chemm ... unverifiable ... TAKEN AS GIVEN and cannot be contested'
MPEP § 2131 / § 2112 — a claimed value must be disclosed or necessarily present; inherency cannot rest on 'presumably'Evidence needed: Obtain and verify chemm.hhs.gov pg. 11 to confirm whether it reports any NACA (as opposed to NAC) plasma concentration.
Risk The examiner will point to the 600 mg example in Arad (para. 120) and argue plasma levels 'may be expected to be higher,' and reassert inherency. Because chemm was never retrieved, this argument cannot be advanced as dispositive until the reference is obtained; overstating it risks an examiner correction. Prosecution-history caution: arguing the specific NACA numeric range is unmet may be read as a disclaimer if the ranges are later amended.
Likely examiner response⚠ fragile — the comeback likely defeats it
A realistic examiner rebuttal: chemm.hhs.gov is taken as given and cannot be contested on this record, and the examiner can maintain it (with the Spada/inherency premise) supplies the PK teaching, treating the recited NACA range as the inherent result of the obvious composition/dose and shifting the burden to applicant (MPEP § 2112.01). Because the NPL content is stipulated-as-given, the examiner can characterize the applicant's position as attacking an unverifiable reference rather than showing the range is absent.
How to adjust This is expressly provisional/verify-first and non-dispositive: obtain and verify chemm.hhs.gov pg. 11 BEFORE relying on it. If chemm reports only a NAC peak and no NACA value, this folds into argument 4's inherency-necessity attack and should be run through that vehicle, not as a stand-alone missing-element point (a § 102-style 'missing element' framing is inapt if the rejection is § 103). If the NACA PK is genuinely unsupported anywhere in the record and applicant has data, prefer establishing it by declaration or amendment rather than by argument on an unverifiable NPL.
the lactose
The examiner rejects claim 6 under § 112(b) because claim 2 (the base claim) recites 'lactose monohydrate,' not 'lactose,' leaving 'the lactose' without express antecedent basis. For counsel to weigh: one lever is a claim-construction position that 'lactose monohydrate' in claim 2 supplies antecedent basis for 'the lactose' in claim 6 because lactose monohydrate is a lactose, so the scope is reasonably certain under BRI (In re Packard / MPEP § 2173.02); the cleaner path is a conforming amendment to recite 'the lactose monohydrate.' This is a minor formal defect and is ranked last.
- —Office action § 112(b) rejection: 'Claim 6 recites the limitation "the lactose" in line 1 of claim 6. There is insufficient antecedent basis for this limitation in the claim.'
- —Claim 2: 'selected from microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and stearic acid'
MPEP § 2173.05(e) — lack of antecedent basis; § 2173.02 / In re Packard — examination definiteness standard (BRI, clarity of scope)
Risk The examiner may maintain that 'lactose' and 'lactose monohydrate' are not coextensive terms, so the antecedent-basis defect stands absent amendment. A conforming amendment resolves it without argument; no meaningful PHE concern.